YUHAN CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 125,000.00 KRW | +0.16% |
|
-0.48% | +81.69% |
| 08-22 | South Korean Shares Rise After BOK Rate Hold; Yuhan Gains on FDA Approval | MT |
| 08-22 | Yuhan Shares Jump 4% After US FDA Approves Anti-Cancer Drug for US Markets | MT |
Sales 2023 by Business Segment
Sales 2023 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Biotechnology (Startups) | 1,480B | 1,620B | 1,688B | 1,776B | 1,859B | |||||
Total Assets | 2,117B | 2,394B | 2,464B | 2,473B | 2,814B | |||||
Interest Expense | -3.1B | -2.71B | -2.94B | -3.47B | -6.3B | |||||
Income Tax Expense | 18.31B | 49.49B | 26.93B | 4.33B | 508M | |||||
CAPEX | -46.73B | -91.18B | -81.87B | -102B | -161B | |||||
EBT | 54.92B | 240B | 126B | 94.93B | 135B | |||||
D&A | 58.66B | 59.78B | 52.67B | 43.02B | 44.68B | |||||
Net Income | 40.01B | 193B | 103B | 95.14B | 136B |
Geographical Revenue Distribution History
| Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
South Korea | - | - | - | - | - | |||||
Interest Expense | - | - | - | - | - | |||||
Income Tax Expense | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
Net Income | - | - | - | - | - | |||||
EBT | - | - | - | - | - |
- Stock Market
- Equities
- A000100 Stock
- Financials Yuhan Corporation
- Business Segments
MarketScreener is also available in this country: United States.
Switch edition